beta
/OA06.01 A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC
Abstract

Abstract N/A

RelatedView All
CitationsView All
Citing-
Cited By-